Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

24.09 -0.38 (-1.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its... 
Via StockStory
Topics Artificial Intelligence
4 Things You Need to Know if You Buy Moderna Stock Today
Via The Motley Fool
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
2 No-Brainer Biotech Stocks to Buy Right Now
Via The Motley Fool
Moderna Unusual Options Activity
 
Via Benzinga
Which S&P500 stocks are gapping on Wednesday?
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
MarketBeat Week in Review – 03/10 - 03/14
Stocks continued to be under pressure on concerns over tariffs and growing inflation concerns, but history shows that corrections can set up opportunities 
Via MarketBeat
Topics Economy World Trade
Down 93%, Is It Finally Time to Buy Moderna?
Via The Motley Fool
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)
 
Via Benzinga
3 Reasons MRNA is Risky and 1 Stock to Buy Instead
Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per share. This was partly due to its softer quarterly results and might have... 
Via StockStory
Top S&P500 movers in Tuesday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Gapping S&P500 stocks in Tuesday's session
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Tuesday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains. 
Via MarketBeat
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
Where Will Vertex Pharmaceuticals Be in 10 Years?
Via The Motley Fool
BioNTech Surpasses Q4 Revenue Estimates
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue. 
Via The Motley Fool
Okta, Moderna and MicroStrategy Are Among Top 10 Large-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?
Top performing large-cap stocks last week: Okta, Moderna, Arcelor Mittal, MicroStrategy, ING Groep, POSCO, Elbit Systems, Trip.com, Eventbrite, Gold Fields, Rocket Companies. 
Via Benzinga
Stay informed with the top movers within the S&P500 index on Friday.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week. 
Via Investor's Business Daily
Topics Intellectual Property
FDA Nominee Marty Makary Faces The Senate. Will He Toe The RFK Jr. Line?
A Senate committee will vote Thursday on whether to endorse Dr. Marty Makary as the new commissioner of the Food and Drug Administration. 
Via Investor's Business Daily
What's going on in today's pre-market session: S&P500 movers
Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session. 
Via Chartmill
Why Moderna Stock Zoomed Nearly 16% Higher on Wednesday
Via The Motley Fool
Exploring the top movers within the S&P500 index during today's session.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Discover which S&P500 stocks are making waves on Wednesday.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Wednesday's pre-market session: top gainers and losers in the S&P500 index
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment. 
Via Chartmill
Coatue's Philippe Laffont Just Bought Shares of This Beaten-Down Growth Stock That Wall Street Predicts Will Soar 80%
Via The Motley Fool
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback